title: Cytomegalovirus as an oncomodulatory agent in the progression of glioma.
abstract: Glioblastoma multiforme (GBM) is the most aggressive neoplastic brain tumor in humans with a median survival of less than 2 years. It is therefore critical to understand the mechanism of glioma progression and to identify future targets for intervention. We investigate the mechanisms of cytomegalovirus as an oncomodulatory agent implicated in glioma progression, as well as immunosuppression. This review provides a comprehensive evaluation of recent investigative developments concerning the role of CMV in cellular processes during glioma growth. The manners in which CMV and its viral products interact with regulatory cellular signaling pathways in the host are of primary interest. Here, we examine some of the most significant oncomodulatory effects that CMV can confer in brain tumors, including the inhibition of apoptosis and promoting the growth of glioma stem cells, which are tightly linked to tumor survival and recurrence.
authors: Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, 550 17th Avenue, Seattle, WA 98122, USA.
authors: Gabriel P
authors: GP
authors: Joseph
authors: Department of Neurosurgery, University of San Antonio Medical Center, San Antonio, TX 78219, USA.
authors: Ryan
authors: R
authors: McDermott
authors: Institute of Experimental Diagnostic and Biotherapy, N.N. Blokhin Cancer Research Center (RONC), Moscow, 115478, Russia.
authors: Maria A
authors: MA
authors: Baryshnikova
authors: Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, 550 17th Avenue, Seattle, WA 98122, USA.
authors: Charles S
authors: CS
authors: Cobbs
authors: Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, 550 17th Avenue, Seattle, WA 98122, USA; Institute of Experimental Diagnostic and Biotherapy, N.N. Blokhin Cancer Research Center (RONC), Moscow, 115478, Russia. Electronic address: Ilya.Ulasov@Swedish.org.
authors: Ilya V
authors: IV
authors: Ulasov
mesh_terms: D000818:Animals; D017209:Apoptosis; D001932:Brain Neoplasms / Q000453:epidemiology / Q000276:immunology / Q000473:pathology / Q000821:virology*; D002453:Cell Cycle; D049109:Cell Proliferation; D002472:Cell Transformation, Viral; D003587:Cytomegalovirus / Q000276:immunology / Q000378:metabolism / Q000472:pathogenicity*; D003586:Cytomegalovirus Infections / Q000453:epidemiology / Q000276:immunology / Q000378:metabolism / Q000821:virology*; D018450:Disease Progression; D005910:Glioma / Q000453:epidemiology / Q000276:immunology / Q000473:pathology / Q000821:virology*; D054884:Host-Pathogen Interactions; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D019139:Tumor Escape; D014412:Tumor Virus Infections / Q000453:epidemiology / Q000276:immunology / Q000378:metabolism / Q000821:virology*
chemical_list: D018836:Inflammation Mediators
keywords: Brain tumor; CMV; Glioblastoma; Oncomodulatory agent